| Biomarker ID | 1299 |
| PMID | 24394557 |
| Year | 2014 |
| Biomarker | CTGF |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.15 (95% CI: 1.02–1.29) |
| Effect on Pathways | Pathways include: YAP1- and WWTR1 (TAZ)-stimulated gene expression, Alpha-M beta-2 integrin signaling, RAGE pathway, Lipid metabolism regulation by peroxisome proliferator-activated receptor alpha (PPAR-alpha), Fatty acid, triacylglycerol, and ketone body metabolism |
| Experiment | PCa Specific Survival Vs No PCa Specific Survival |
| Type of Biomarker | Prognostic |
| Cohort | 189 patients from Swedish Cohort were selected for analysis. Survival information was available for 185 patients. 22 are alive, 98 died due to prostate cancer and 65 died due to other causes.100 samples were available for the analysis of this gene |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.023 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CTGF |